ライブ

CellMultimodal imaging of gene expression, morphology, and activity of the same neuron FierceBiotechFDA warning slams Zoll Medical with multiple quality control and reporting violations BioWorldHangzhou Innogate Pharma discovers new KAT inhibitors BioWorldAlicorn synthesizes new AAK1 inhibitors BioWorldChinese scientists identify new macrocyclic compounds as kinase inhibitors BioWorldNew VAV1 degradation inducers reported in Haisco Pharmaceutical Group patents BioWorldNankai University and Accendatech present new majusculamide D derivatives LabiotechThe Naming Patterns Behind 12,000 Biotech Companies Endpoints NewsUS government launches probe into Germany's plan to pay less for drugs LabiotechBIO International Convention 2026: practical advice from former Evotec CEO Werner Lanthaler Science Daily BiotechThis giant tropical fruit could help reverse gum disease damage eLifeMetabolic support of trained immune responses in myeloid cells

BioWorld 2026年6月19日

Chinese scientists identify new macrocyclic compounds as kinase inhibitors

Henan Normal University and Henan Zhiwei Biological Engineering Co. Ltd. have discovered macrocyclic compounds acting as neurotrophic tyrosine kinase receptors...

Henan Normal University and Henan Zhiwei Biological Engineering Co. Ltd. have discovered macrocyclic compounds acting as neurotrophic tyrosine kinase receptors (TRK) and/or proto-oncogene tyrosine-protein kinase ROS (ROS1; MCF3) and/or hepatocyte growth factor receptor (HGFR; MET) and/or macrophage colony-stimulating factor 1 receptor (CSF1R; CD115; c-Fms) and/or ALK tyrosine kinase receptor inhibitors found to be potentially useful for the treatment of cancer and pain.